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The sole envelope glycoprotein spike on the surface of Human Immunodeficiency 
Virus (HIV-1) is composed of two subunits: gp120 and gp41. The gp120 consists of 
three domains: the inner domain, outer domain and bridging sheet, to which the viral 
primary receptor CD4 binds and induces a conformational change in gp120 to expose 
the co-receptor binding site. Previous studies have found that the outer domain of 
gp120 is relatively more stable than the inner domain and bridging sheet. When 
superimposed, the co-crystal structures of CD4-gp120 complex and VRC01-gp120 
complex revealed that the CD4-binding site (CD4-BS) antibody VRC01 actually 
mainly bound to the outer domain of the gp120. The outer domain (designed OD1) of 
gp120 has been considered as an immunogen candidate but to be ineffective, 
suggesting that structural-based modifications to the outer domain are required for 
designing an effective vaccine immunogen. Previous studies in our laboratory have 
introduced two disulfide bonds to stabilize the outer domain structure and named it 
OD2, which significantly improved the immunogenicity when compared to the wild-
type outer domain (OD1). In this project, based on the OD2 set of experiment, an 
additional important mutation from serine to tryptophan at position 375 (S375W) in 
the CD4-binding cavity was introduced to further stabilize the outer domain, which 
was named OD3. The OD3 immunogen was expressed and purified in E. coli. 
Subsequently, the purified OD3 immunogen was characterized in vitro and its 
immunogenicity was tested in guinea pigs. In comparison to OD1 and OD2, the 
results demonstrate the antibody titers and neutralizing activity were clearly higher in 
OD3. It is suggested that the S/375W mutation stabilized the outer domain and further 
improved the outer domain (OD) immunogenicity. In conclusion, this research has 
used a structure-based approach to design HIV-1-1 vaccine immunogens based on the 
gp120 outer domain (OD).  
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Chapter 1: Literature review 
Acquired immune deficiency syndrome, known as AIDS, is an immunodeficiency 
disease caused by human immunodeficiency virus type 1, known as HIV-1-1. Since the 
virus was discovered in 1981(1-4), more than 65 million people have been infected with 
this virus, and more than 39 million people have died of AIDS-related diseases (5). An 
astonishing fact is that the number of deaths caused by AIDS exceeds the total number 
of death resulted from all the wars in the 20th century. Although scientists try to 
elongate HIV-1 patients’ life to a higher extent, we currently still have no cure, and 
have no effective vaccine to prevent the virus infection. While researchers all over the 
world have united together to tackle this problem, there are still a lot of obstacles on 
the way to the success. The year 2014 was sad for us: MH17, an aircraft taking more 
than 100 HIV-1 field experts crashed by a missile attack, and no one survived this 
disaster (6). While people in the whole world were criticizing the missile attack, 
scientists in HIV-1 related field were grieving over the deaths of their colleagues. Yet 
we are, and will still be working on this issue: public awareness has been raised 
dramatically in developing countries; vaccine development is becoming promising; 
antiviral therapeutic treatments are also becoming more effective. In the foreseeable 
future, human beings will finally overcome this disease. 
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Acquired Immune Deficiency Syndrome (AIDS) 
AIDS is caused by HIV-1-1 infection. HIV-1-1 specifically attacks human immune 
cells such as CD4+ T cells, dendritic cells and macrophages (7). The infected 
lymphocytes are recognized as toxic pathogens by human cytotoxic CD8+ lymphocytes, 
and are killed by them. When CD4+ T cells and other vital human lymphocytes decline 
to a certain critical level, cell-mediated immunity is gradually destroyed, and people 
infected with HIV-1 eventually die from the breakdown of their immune system. 
Without any treatment, this whole process may take 9-12 years (8). 
Human Immunodeficiency Virus （HIV-1） 
Facts and Statistics 
AIDS-related diseases have led to a total number of 39 million death since 1981, the 
first reported case. In 2015, there were 37 million people living with HIV-1-1, and Sub-
Saharan Africa accounts for 70% of HIV-1-1-infected population. Although we have 
witnessed an increase of incidence in two years, the death rate and HIV-1-1-infected 
growth rate has dropped down significantly. New HIV-1-1 infections have fallen by 35% 
since 2000, and new HIV-1-1 infections among children have declined by 58% since 
2000. By the end of 2015, AIDS-related deaths have fallen by 42% since the peak in 
2004. By the year 2015, 5.8 million people were accessing antiretroviral therapy and 
16 million of people had received antiretroviral therapy (ART) (5). With ART, people 
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living with HIV-1-1 are able to have their lives extended to 30 or more years, making 
their future promising (9). 
HIV-1 Evolution and Genetic diversity 
HIV-1 belongs to the genus lentivirus, which is a part of the family Retroviridae 
(10)(11). HIV-1 is an enveloped, positive, single-stranded RNA virus. It was first 
reported as syndrome caused by a new virus in 1981. It was then named HIV-1 in 1982, 
and was finally isolated and characterized in 1983 (4). There are two types of HIV-1, 
classified as HIV-1-1 and HIV-1-2. HIV-1-2 originates from a simian 
immunodeficiency virus (SIV) that infects the Sooty Mangabey. Compared to HIV-1-
1, HIV-1-2 is less infectious, less virulent, and thus is confined primarily to West Africa 
(12). HIV-1-1 originates from an SIV which infects common chimpanzees and gorillas. 
HIV-1-1 is divided into 4 groups, one major group named M group, and three minor 
groups named group N, O and P.  Each group is believed to represent an independent 
transmission of SIV into humans (13). The M group accounts for 90% of HIV-1-1 
infections all over the world and is further divided into 11 clades, or subtypes. They are 
named alphabetically from A to K. Among the subtypes, subtype A is most commonly 
seen in West Africa; subtype B is widely spread in Europe, United States, Australia, 
Thailand and Japan; and subtype C is the dominant from southern and eastern Africa, 
India, and parts of China. Other subtypes are less transmissible and confined to smaller 
areas (14).  
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HIV-1 Transmission 
The three major transmission pathways of HIV-1 are sexual contact, direct exposure to 
infected blood or body fluids, and mother to child transmission during pregnancy or 
breastfeeding (15). It is confirmed that other routes of transmission such as exposures 
to feces, sweat, tears, or saliva (16). Among these three transmission pathways, sexual 
contact (both heterosexual and homosexual contact) is responsible for the most frequent 
transmission. Generally, HIV-1 transmission via heterosexual contact dominates 
among all the transmission pathways worldwide, however, the incidence of homosexual 
transmission is arising in developed countries (17). In Africa, the majority of 
transmissions are through mother to child, and male to female sexual contact. However, 
homosexual contact results in higher percentage of HIV-1-1 infection in some European 
countries and the United States, which accounts for 64% of new cases of infection(18). 
Oral sexual contact also transmit HIV-1-1 through blood from minor wounds, although 
the risk of this is relatively low (19). The risk of transmission may increase when there 
are other sexually transmitted infections (20) or ulcers (18). When genital ulcers are 
exposed to infected blood or body fluids, the result is a five-fold increase of HIV-1-1 
infection (18). The most effective protection in sexual pathway is the use of condoms 
during any sexual intercourse, which can reduce the risk of transmission by 73%. (21).  
 
Blood and body fluid transmissions account for the second most frequent mode of HIV-
1-1 transmission. This is particularly true in less-developed counties. By sharing 
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needles and needle stick injuries, blood and blood product transfusions, or medical 
injections with contaminated and unsterilized instruments, HIV-1-1 finds its way to 
lead to a positive infection. In developed countries, examination of blood products 
before a blood transfusion is conducted is usually very seriously considered, and thus 
the risk of HIV-1-1 infection is negligible (about 1 in 1.5 million in the United States 
in 2008) (22). While in less developed countries, HIV-1-1 screening and blood donor 
selection are not conducted perfectly, so up to 15% of HIV-1-1 infections in those 
countries actually comes from contaminated blood and blood product transfusions 
(23)(24) 
 
Mother-to-child is the third most frequent mode of HIV-1-1 transmission. This 
transmission pathway causes 90% of cases in children infected with HIV-1-1 (25). 
However, with appropriate treatment during pregnancy, the risk of mother-to-child 
infection can be reduced to about 1% (25). A piece of good news is that during the year 
2014, there were 220,000 cases of children who became newly infected with HIV-1-1, 
decreasing from 520,000 in 2000 (5). 
HIV-1-1 structure and genome 
As shown in Figure 1, HIV-1-1 is positive, single-stranded RNA retrovirus. Two copies 
of RNA strands are packaged in the viral capsid and enveloped by matrix protein and 
lipid membrane. HIV-1-1 is roughly spherical (26). Its diameter is about 120 nm, which 
is 60 times smaller than a human red blood cell (27). Viral RNAs carry all the genetic 
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information and are the nucleotides materials responsible for encoding nine structural 
and non-structural proteins. As shown in Figure 2, the whole genome contains 9749 
base pairs, and nine open reading frames which are protected by two long terminal 
regions on both the 3’ and 5’ sites. Among the nine open reading frames, there are three 
large precursor proteins, named Gag, Pol and Env (28). These proteins are then post 
transcriptionally cleaved into smaller structural and non-structural proteins. The viral 
RNAs are tightly bound and protected by the nucleocapsid protein p7, and the late 
assembly protein p6. Viral RNA-P7-P6 complex is carried by the capsid made up of 
2000 copies of p24 (29) (30), and further covered by the matrix protein composed of 
p17. All of these proteins are post transcriptionally cleaved from the Gag precursor 
protein. The three most important non-structural proteins: integrase, reverse 
transcriptase, and viral protease, are encoded in the Pol open reading frame. Regulatory 
proteins such as Rev and Tat, and other auxiliary accessory proteins, such as Vpr, Vif, 
Vpu, and Nef are encoded in smaller open reading frames (31) . Outside the matrix is 
the lipid membrane layer. It is formed from human lymphocytes by taking the 
advantage of their lipid bilayer. HIV-1-1 envelope glycoproteins gp120 and gp41 are 
cleaved from their gp160 precursor encoded from Env open reading frame. These two 
envelope protein subunits play a vital role in viral entry, and thus are the key to inhibitor 
design and vaccine development (32, 33). 
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HIV-1-1 Viral Life Cycle 
HIV-1-1 lives in human lymphocytes. HIV-1-1 becomes very fragile when it is exposed 
in the environment outside of the body (34, 35), which reduces the amount of infectious 
virus by 90%-99% in just several hours. However, when HIV-1-1 is exposed to a human 
lymphocyte, this virus finds its way into it and makes the human lymphocyte a 
reproductive reservoir. The CD4 molecule binds to gp120, followed by a significant 
conformational change, which leads to the exposure of chemokine receptor on gp120. 
On the surface of the cell, the chemokine receptor, either CCR5 or CXCR4, then binds 
to gp120, which allows gp41 to penetrate the cell membrane, and thus fuels virus-cell 
membrane fusion (34, 35).  
 
Successful viral fusion results in delivery of viral RNA and non-structural proteins into 
the cell. These important enzymes, including reverse transcriptase (RT), integrase, 
protease, etc., serve in reverse-transcription, cDNA replication, and host genome 
integration. Reverse transcriptase transcribes the single strand viral RNA into a 
complementary DNA carrying viral genetic information. The cDNA and its 
complement form a double-stranded viral DNA and the viral protease and integrase 
insert viral DNA into human host chromosome (34, 35) . During replication and 
transcription, the extremely error-prone reverse transcriptase generates cDNA with a 
large number of mutations, which can result in immune evasion and drug resistance. 
8 
Other unique features about the reverse transcriptase are its ribonuclease activity and 
DNA-dependent DNA polymerase activity (36, 37). 
 
NF-B is one of the cellular transcription factors that controls virus production after the 
viral genome has been successfully integrated into the host chromosome (38). When 
cytotoxic CD8+ T-cells become activated, NF-B is upregulated and allows the host 
genome to actively produce viral particles. Viral non-structural and structural proteins 
are produced along with host chromosome translation. During viral replication, the 
integrated viral DNA is transcribed back into viral RNA, which then undergoes RNA 
splicing and becomes viral mature mRNAs (39). Along with the translation, some viral 
regulatory enzymes, including Tat, allows better viral production. Another enzyme, 
Rev, can localize itself to the nucleus and bind to viral mRNA, making the viral mRNA 
possible to transport out of the nucleus. With Tat and Rev, viral mRNAs leave the 
nucleus (38), and these mRNAs either function as transcription and translation 
materials, to produce viral non-structural or structural proteins, or function as new viral 
genome copies. Viral mRNAs, structural proteins and non-structural proteins, are then 
packaged and assembled in the Golgi apparatus, and leave the host cell when mature. 
During maturation, the Env polyprotein gp160 is cleaved by furin protein in the Golgi 
apparatus. The cleaved gp160 becomes two subunits, gp120 and gp41, which are non-
covalently linked and form a heterodimer. Three gp120/gp41 heterodimers form a 
homotrimer anchored by gp41 subunits on the surface of HIV-1-1 envelope. Virions 
are finally become mature and are then able to infect neighboring cells (40, 41). 
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Immune Response 
Signs and Symptoms 
When having unprotected sex with an HIV-1-1 infected individual, or having direct 
exposure to HIV-1-1 infected blood or body fluid samples, people are at risk of getting 
infected with HIV-1-1. Initial symptoms may be inconspicuous since large numbers of 
individuals only develop influenza-like symptoms (42)(43), and some others have no 
noticeable symptoms (44)(45). Most commonly reported initial HIV-1-1 symptoms are 
fever, lymphadenopathy, rash, headache, and throat/mouth/genital inflammation (46). 
Some opportunistic infections like gastrointestinal symptoms, and neurological 
symptoms may occur (47). However, all symptoms are not severe, and usually 
disappear without any treatment in one to two weeks (48). Considering the fact that 
these symptoms are usually not specific, and are easy to “be cured”, HIV-1-1 infections 
are often not being recognized or diagnosed. Typically, people who had unprotected 
sex with an individual with HIV-1-1 before developing with such symptoms, are 
suggested to have a HIV-1-1 antibody test 1-3 months after suspecting that they have 
been exposed to HIV-1-1.  
 
In most cases, an HIV-1-1-infected individual first develops the non-specific Flu-like 
symptoms described above, then the immune system starts to eliminate the virus but 
leaves some latent virus harboring in CD4+ T cells, Macrophages or Dendritic cells 
(49). A patient will live normal life until HIV-1-1 progresses and AIDS or AIDS-related 
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symptoms arise after several years. Without any treatment, this clinical latency may last 
three to 20 years, with an average of eight years (50)(51)(52). During the latency, 
patients may first experience asymptomatically, or just have a low-grade fever for a 
short period of time, but at a later latency stage, CD4+ T cells are lost at a higher rate 
and individuals will eventually progress to AIDS (53). Interestingly, there are some 
exceptions: about 5% of HIV-1-1 infected individuals actually retain a high level of 
CD4+ T cells for more than five years without any treatment (54)(55), these people are 
known as “long-term non-progressors” (55); another group is known as “elite 
suppressors” whose viral load is undetectable even without any treatment.  
 
AIDS refers to HIV-1-1 post latency symptoms and AIDS associated diseases, which 
is clinically defined by the number of CD4+ T cells declined to a certain critical level 
(usually, below 200 CD4+ T cells per microliter) (56). Without any antiretroviral 
treatment, individuals infected with HIV-1-1 develop these symptoms within 10 years, 
and swiftly progress to death due to the depletion of the vast majority of CD4+ T-cells 
and infectious virus domination in plasma. Opportunistic infectious disease develops 
along with this stage and can be caused by almost any pathogens including bacteria, 
viruses, fungi and parasites (57). HIV-1-1 patients at a later clinical state are also very 
vulnerable to cancers. Kaposi’s sarcoma occurs in 10 to 20% of cases of HIV-1-1 
infected patients, which becomes the most common cancer accompanying AIDS (58). 
Lymphoma, leading to death in 16% of people living with HIV-1-1, is the second most 
common cancer (59). Human papillomavirus (HPV) and Hepatitis C virus (HCV) are 
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reported to co-infect with HIV-1-1 and these two viruses also lead to virus-induced 
cancers. 
Innate Immunity 
Innate immunity refers to the non-specific in-born immunity. Innate immunity plays a 
very important role in early HIV-1-1 defense. The innate immunity is also the sub-
immune system that bridges humoral and cell mediated adaptive immune response at a 
later stage. Moreover, white blood cells serve in innate immunity and in the case of 
HIV-1-1 infection, play a unique role in HIV-1-1 latency, which is a major barrier of 
HIV-1-1 eradication. 
 
During the first stage of HIV-1-1 infection (also referred to as acute HIV-1-1 infection), 
HIV-1-1 viral particles can be recognized by phagocytes such as macrophages and 
dendritic cells (60, 61). HIV-1-1 envelope proteins, viral mRNAs, and other viral 
structural or non-structural proteins, are termed as viral pathogen-associated molecular 
patterns (PAMPs) (61). These viral PAMPs are recognized by pathogen-recognition 
receptors (PRRs) of infected cells which trigger a series of signaling cascades. These 
signaling cascades result in an intracellular antiviral immune response such as a 
production or upregulation of antiviral molecules including interferons, interleukins, 
cytokines and chemokines (60) . These molecules and the phagocytes are also involved 
in initiation of the adaptive immune system(62) . At the first infection stage, HIV-1-1 
is recognized by a mode of PRR termed as Toll-like receptors (TLRs) (63). Among 
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these TLRs, plasmacytoid dendritic cells (pDCs) unitize TLR7 and TLR9 to recognize 
single-stranded RNA (ssRNA) and double-stranded DNAs (dsDNAs) (63), triggering 
signaling cascades to control viral replication and reproduction.  
 
Viral replication usually indicates a successful viral infection, however, in the case of 
pDCs, TLR7 and TLR9 recognition usually does not require HIV-1-1 reproductive 
infection (63). There therefore must be other PRRs recognition pathways being 
activated in those infected cells. It has been demonstrated that the infected cells use 
RIG-I-like receptors (RLR) and other PRRs such as DAI, IFI16, and AIM2 to recognize 
viral DNAs. Biological interplay between viral DNAs and PRRs leads to transcriptional 
activation of pro-inflammatory cytokines, chemokines, and type I interferons (I-IFNs) 
(64, 65). For example, upon TLR7 recognition, I-IFNs are induced, and these IFNs bind 
to IFN receptors on the surface of the infected and surrounding cells, which further 
triggers other signaling cascades that activates the transcription and translation of many 
IFN-stimulated genes (ISGs). ISGs are important in blocking viral replications. One of 
the most important ISGs is IFI16 (66-68). As mentioned above, IFI16 serves a role as 
PRR. IFI16 is both a nuclear and a cytosolic protein. This protein binds to cDNA under 
the assistance of a hin domain (67). After HIV-1-1 has successfully entered and 
replicated in the reservoir, the viral mRNAs are reversely transcribed into cDNA. IFI16 
recognizes and captures viral DNA through hin domain, destroying HIV-1-1 
replications (69). A knockdown of IFI16 study shows that the target host cells that 
undergo HIV-1-1infection in the absence of IFI16, have a significant higher level of 
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HIV-1-1 permissiveness and viral replication(68). Thus IFI16 are confirmed to be both 
an HIV-1-1 PRR and a restriction factor. 
 
RLRs are a family of DExD/H box RNA helicases that function as cytoplasmic sensors 
of PAMPs. Among these RLRs, RIG-I functions in HIV-1-1-infected cells by binding 
to HIV-1-1 mRNAs (70), which leads to activation of pro-inflammatory innate 
immunity response to target cells. Importantly, RIG-I also contributes to crosstalk with 
TRLs and other PRRs to modulate the adaptive immune response (71). Another sensor 
that recognizes HIV-1-1 PAMPs in HIV-1-1-infected cells is the cyclic GMP-AMP 
synthase (cGAS) (69), which recognizes and binds to HIV-1-1 reverse transcriptase in 
its early replication cycle. cGAS contains an amino-terminal DNA binding domains 
and a nucleotidyltransferase domain, which allows viral DNA binding and produces 
cyclic GMP-AMP (cGAMP) (68, 72). cGAMP is a cellular factor that works along with 
cGAS to induce ISGs. cGAMP also functions as a second signaling factor and binds to 
an adaptor protein called STING. The cGAMP-STING complex activates a signaling 
cofactor TBK1, and interferon regulatory factors INF3 and INF7 (72), which finally 
stimulates antiviral effector genes. Transcriptional factors such as IRF3, IRF7 and NF-
kB, also drive the production of viral restriction factors (APOBEC, TRIM5a, SAMHD1, 
and tetherin) (61, 73) limiting viral replication. Each of these factors has been heavily 
studied. Recent studies found other restriction factors including SLFN11, IFITM and 
MX2 (74-77). Interestingly, these factors are not highly expressed in resting cells only 
until they are induced by IFN. SLFN11 is an RNA helicase-like protein that suppresses 
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HIV-1-1 replication at a later stage, so it is also associated with control of HIV-1-1 
chronic infections. IFITM is transmembrane protein that inhibits HIV-1-1 entry (77). 
MX2 is GTPase that suppresses HIV-1-1 replication by stopping HIV-1-1 reverse 
transcribed DNA integration into the host chromosome.  
 
During the first few hours of HIV-1-1 infection, viruses successfully obtain 
opportunities to tear into the mucosal epithelium and undergo further interactions with 
conventional DCs (cDCs) and Monocytes (60). The HIV-1-1-bearing stromal cDCs 
also have CD4 molecule and CCR5 coreceptor on the cell membrane for HIV-1-1 
infection. Activation of cDCs leads virus degradation by the secretion of restriction 
factors such as APOBEC3G and SAMHD1, to restrict HIV-1-1 replication (78). Also, 
IFNs and Interleukins such as IL-12, IL-15 and IL-18 induced by the activated cDCs 
are able to either inhibit viral replication or recruit the NK cells to kill the infected cDCs 
(79) . However, HIV-1-1 uptake by the C-type lectin DC-SIGN on the surface of the 
DC cell membrane blocks DC maturation thus resulting in DC dysfunction (80). DC-
SIGN binds to HIV-1-1 envelope glycoproteins to internalize virus by endocytosis. 
Binding of DC-SIGN with HIV-1-1 envelope glycoproteins also facilitates HIV-1-1 
transmission to CD4+ helper T cells. During the activation of cDCs, the plasmacytoid 
DCs are also activated. pDCs recognition of HIV-1-1 is achieved by TLR7 and TLR9 
recognition. Unlike cDCs, the recognition usually does not require productive HIV-1-
1 infection. Both cDCs and pDCs interacts with CD4+ helper T cells and transmit 
virions via the virological synapse cell (81, 82). Based on the new understanding of the 
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viral transmission pathway, new ideas of blocking HIV-1-1 infection of CD4+ helper 
cells could be reconsidered, and this understanding also bring us more insights into 
HIV-1-1 antiretroviral drug design as well as vaccine development. 
Acquired Immunity 
Currently, many studies have shown a strong link between the activation of innate 
immunity pathways and the adaptive immunity response (83, 84). Both the severity and 
the duration of primary HIV-1-1 infection are associated with the speed of CD4+ T 
cells lost in chronic infection, and they also positively correlate with the number of 
deaths in the AIDS phase. So, the events during very early HIV-1-1 infection directly 
have consequences for the disease. How does the immune activation indicate HIV-1-1 
infection? It has been well recognized that HIV-1-1 pathogenicity is characterized by 
both severe immunodeficiency and significant immune activation (85, 86). There is 
growing evidence showing that lymphocytes obtained from HIV-1-1-infected patients 
are found mostly in an activated stage (87). During the acquired immunity activation, 
phenotypic activation markers on the surface of peripheral T cells and B cells are 
expressed at a decently higher level regulated by IFNs and other regulatory factors 
induced in the innate immunity phase, shown by an increased level of inflammatory 
cytokines in plasma. A sooty mangabey monkey model study (88) suggested a positive 
correlation between immune activation and immune deficiency. In the absence of 
dramatic immune activation, sooty mangabeys infected with SIV showed no manifests 
of infection but detected high level of SIV replication in plasma (89).  
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Cell Mediated Immunity and Viral Immune Evasion 
The acquired immunity against HIV-1-1 begins with the uptake of virus by CD4+ T 
helper cells. During initial infections, usually a few hours post HIV-1-1 uptake by either 
pDCs or cDCs (90-92), the internalized HIV-1-1 virions are transmitted from DCs to 
CD4+ T cells via virological synapse. HIV-1-1 recognizes and binds to CD4+ T cells 
through the interplay between viral envelope protein gp120 and cellular membrane 
receptor and coreceptor CD4 and CCR5 or CXCR4, followed by CD8+ cytotoxic T 
cells killing infected CD4+ T cells (93). During the first week, HIV-1-1 rests in HIV-
1-1-bearing T lymphocytes and amplifies within the cells in draining lymph nodes. 
HIV-1-1-bearing DCs present HIV-1-1 antigens to both CD4+ T cells and CD8+ T cells 
via either MHC class II AND MHC class I (94). This activation of T lymphocytes in 
draining lymph nodes results in the clonal expansion of HIV-1-1-specific CD8+ T cells 
and HIV-1-1-specific B cells. After activation, HIV-1-1-specific antibodies generated 
from B cell follicle start to neutralize viral particles and CD8+ T cells begin to eliminate 
HIV-1-1 productively infected CD4+ T cells. 
 
Typically, during virus progression, the activated adaptive immunity eliminates both 
viruses and virus-infected cells. However, the outcome of HIV-1-1 infection is that after 
about 10 years of HIV-1-1 latency (95), infected individuals finally end their lives in 
immunodeficiency resulted AIDS. So, what are the reasons make our immune system 
abnormal? And how does the virus escape from immune detection and establish viral 
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latency? Unlike other viruses which target on non-lymphocytes, our working immune 
system clears HIV-1-1-infected CD4+ lymphocytes. This can be achieved by CD8+ 
cytotoxic T cells, and NK cells, cytotoxic killing from which eventually results in 
inadequate CD4+ T cells in plasma. Following initial HIV-1-1 infections, CD8+ 
cytotoxic T cells do help control virus proliferation. The infected cells present viral 
peptide antigens by HLAs (human leukocyte antigens) to CD8+ cytotoxic T cells, 
resulting in apoptosis of infected cells either by perforin generating holes in the target 
cells, by granzymes, or by Fas ligand-Fas (CD95) induced cell death (91). CD8+ 
cytotoxic T cells also regulate the delivery of antiviral soluble factors to infected cells, 
such as cytokines and IFN-gamma, which promote nearby cells becoming less 
vulnerable to viral infection (96)(97)(98). Despite these strategies utilized by CD8+ T 
cells work to some extent eliminated infected cells, the viral defense story is just a 
beginning, for HIV-1-1 is a master of escaping from cytotoxic lymphocytes. Under the 
selective pressure from CD8+ cytotoxic T cells, HIV-1-1 swiftly acquires mutations 
against cytotoxic T cell killing. Strong evidence has been found suggesting two viral 
protein, Nef and Env are responsible for viral immune evasion (99, 100). The Nef 
protein is necessary for high viral loads in AIDS progression, but the most important 
and well characterized function of Nef, is its role in antigen presentation during immune 
evasion. An example is that during an adoptive transfer of cytotoxic T lymphocytes to 
a HIV-1-1-infected patient, the transferred cytotoxic T lymphocytes swiftly and 
effectively selected for viral variants contains a deletion mutation in Nef protein (101, 
102). Another method of immune evasion for HIV-1-1 is that a mutation at the second 
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residue of the Env epitope reduces binding affinity of peptide to MHC during the 
cytotoxic T lymphocyte immune response domination. This result indicates that Env 
mutations can be another immune evasion strategy used by HIV-1-1 during cytotoxic 
T lymphocytes antiviral selection. Other viral proteins that play roles in immune 
evasion include Gag and Pol. These viral proteins allow the virus to replicate without 
recognition by the host (103, 104). 
 
To summarize, strategies of HIV-1-1 escaping cytotoxic T lymphocyte-mediated 
immunity include: If infected CD4+ T cells are successfully eradicated by CTL killing, 
the resulting substantial loss of CD4+ T cells will directly influence T helper cell 
function, and this finally undermines CD8+ T cells immune response to clear infection. 
On the other hand, HIV-1-1 evolves to obtain antigenic variability through the error-
prone-reverse transcriptase resulting in mutations. These viral mutations can result in 
the dysfunction of cytotoxic T lymphocytes in viral recognition, viral replication 
inhibition, or viral proliferation. Eventually, the repeated T cell activation ends in T cell 
exhaustion and leads to chronic HIV-1-1 infection. 
Humoral Immunity and Viral Immune Evasion 
During early HIV-1-1 infection, typically 1-4 weeks post infection, CD4+ T cells 
activated by DCs presenting antigens via MHC II differentiate into T follicular helper 
cells and migrate into the B cell follicle (105, 106)(107). HIV-1-1-specific B cell and 
early antibody responses are established in the interplay of follicular DCs, follicular B 
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cells and follicular helper T cells (108). In the early immune activation stage, pro-
inflammatory cytokines mediated from innate immune response events lead to the 
increase of turnover and polyclonal activation of B cells (109). This however will 
results in either increased B cell apoptosis, follicular hyperplasia, or mature B cell 
activation. A successful B cell maturation and memory B cell differentiation guided by 
HIV-1-1 infection establishes the foundation for HIV-1-1-specific antibody production. 
However, neutralizing antibodies against autologous HIV-1-1 strains develop slowly, 
usually no earlier than 12 weeks post initial infection (110), and what is worse, even 
though about 20% of HIV-1-1 patients develop neutralizing antibodies against HIV-1-
1, a majority of these antibodies are of only moderate degree of neutralization and 
aroused after years of infection (106, 111). It is thus important to look at B cells at their 
early response to HIV-1-1 infection to understand why a neutralizing antibody response 
cannot be acquired in acute infection as is the case in other viral infections.  
 
The first detectable B cell response is found on day 8 post infection, whereas the first 
detectable antibody response appears on day 13 post infection. These early induced 
antibodies are however non-neutralizing antibodies against either gp41 or gp120 (111-
115). It is still unknown why these early phase antibodies are non-neutralizing. One 
possible reason is that denatured or non-functional Env forms may be dominant in the 
antigen pool (116, 117). The first neutralizing antibodies that induce escape mutants 
develop 12 weeks post infection (118-120). Although studies have characterized a 
number of neutralizing antibodies, these neutralizing antibodies majorly bind to the 
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highly conserved regions of gp120 or gp41. For example, the monoclonal antibodies 
b12 and VRC01, neutralize virus by specific binding to the CD4-binding site on gp120. 
Another example would be the monoclonal antibodies that recognize the membrane-
proximal external region of gp41, such as 2F5, Z13 and 4E10 (120). Observations based 
on the neutralizing antibodies binding locus reveal that the HIV-1-1 variable loops 
under highly-shielded glycans create an antigenic barrier for antibodies neutralizing 
either HIV-1-1 envelope core domains, or HIV-1-1 envelope variable loops.  
 
Reasons for the broad-specificity, poor neutralizing, and rarely induced antibodies are 
complex. First, as mentioned above, HIV-1-1 escapes antibody recognition by the error-
prone reverse transcriptase-resulted antigenic mutations. Under antibody selection, 
more than 95% of gp120 nucleotide changes resulted in an amino acid change (121). 
Second, during HIV-1-1 progressive infection, follicular B cells are damaged by virus-
induced and pro-cytokine induced apoptosis. The loss of follicular B cells has a direct 
influence on antibody production, resulting either in a poor antibody response or 
hypergammaglobulinemia. This damage further contributes to substantial loss of 
germinal centers (about 50%) (122) and gradually progresses to HIV-1-1 chronic 
infection. Third, during the chronic and advanced infection, CD4+ T cell lymphopenia 
stimulates the secretion of IL-7, which increases the number of immature transitional 
B cells. The consequence of expansion of immature B cells promotes a declined B cell 
response to HIV-1-1 antigens. In addition, Nef mediated class-switch recombination, 
during the expansion of immature B cells and naive mature B cells, results in the paucity 
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of HIV-1-1-specific lgA at mucosal sites (122). At a later AIDS stage, inadequate CD4+ 
T helper cells are not functional enough to transit the decreased number of resting 
memory B cells or splenic marginal zone B cells into memory B cells, which ends up 
with memory B cell exhaustion. Taken together, the antigenic variability of HIV-1-1 
envelope proteins, the vast damage in both germinal centers and follicular B cells, the 
loss of CD4+ T helper cells and the exhausted memory B cells are eventually not able 
to produce high affinity broadly neutralizing antibodies against HIV-1-1 progression. 
HIV-1-1 Viral Latency 
HIV-1-1 can infect both activated and non-activated, resting CD4+ T cells. Infection of 
activated CD4+ T cells recruits CD8+ T cell cytotoxic killing and results in a substantial 
depletion of CD4+ T cells. Whereas infection of resting CD4+ T cells usually leads to 
viral latency. Viral latency is therefore a major challenge for virus eradication, even 
under the treatment of highly active antiretroviral therapy (HAART) (123). In a normal 
T cell immunity model, naive CD4+ T cells are activated by antigens presented by 
antigen presenting cells (APCs). Following activation, CD4+ T cells start clonal 
proliferation, during which, a majority of T cells undergo apoptosis and some effector 
T cells differentiate into memory T cells. Other naive or memory T cells stay at the G0 
phase of the cell cycle. However, during HIV-1-1 infection, viral genomes are reverse 
transcribed and replicated into double-stranded cDNAs (dscDNAs )(124). The 
dscDNAs are relatively unstable and exist in the cytosol. This is called a reversible pre-
integration latent state. However, when ATP is abundant in the cytosol, pre-integration 
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state dscDNAs are permanently integrated into the host genome. The provirus after 
successful integration remains quiescent before another cycle of immune activation. 
These latent HIV-1-1 provirus bearing CD4+ T cells can be differentiated into memory 
CD4+ T cells (125), and the nightmare for the host starts from here. As the antigens 
fade, most effector T cells die by apoptosis, but a small portion of T cells remains as 
memory T cells, and carry a permanent HIV-1-1 genome in their chromosome (126, 
127). Some of these memory CD4+ T cells transit into a resting state that have an 
extended lifespan and lack the markers for T cell activation. These virus-bearing resting 
CD4+ T cells are thus not recognized by immune system and are less likely to be 
activated during HIV-1-1 progression (128, 129). Viral latency is therefore established. 
Anti-HIV-1-1 Therapy Development against AIDS 
Antiretroviral Therapy 
There is no cure for AIDS at the moment. Neither antiretroviral therapy (ART) nor a 
protective vaccine can eliminate the virus or cure the disease. However, with ART or 
HAART, HIV-1-1 infected individuals are able to live with HIV-1-1 for a longer time 
and have their life extended to a close-to-normal life span. Also, ART does great job in 
preventing mother-to-child HIV-1-1 transmission when treatment is given at a very 
early stage to both child and mother. In the absence of any treatment, mother-to-child 
transmission ranges from 15% to 45%, and ART brings the number down to below 5% 
(130). This ART also provides optimal efficacy of reducing HIV-1-1 transmission 
during sexual contact, reducing viremia and transmission by more than 96% (131)(132). 
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Before given any ART, infected individuals are advised to undergo some tests to 
examine the patient’s medical history, to determine the best choices of medicine, or to 
avoid potential side effects. These tests includes, but not confined to, complete blood 
count (including CD4+ T cell count), urinalysis, liver and kidney function tests, 
infectious disease or sexually transmitted diseases tests, and a coreceptor tropism assay. 
Typically, ART consists of several classes of HIV-1-1 medicines, and each individual 
may take a regimen of different medicines in combination. The anti-HIV-1-1 medicine 
classes are: non-nucleoside reverse transcriptase inhibitors (NNRTIs), which prevents 
HIV-1-1 reverse transcriptase converting viral RNA to cDNA; nucleoside reverse 
transcriptase inhibitors (NRTIs), which also prevents reverse transcription; protease 
inhibitors, which inhibit viral-cleavage of the host genome; fusion inhibitors (e.g. T20), 
which blocks virus-cell membrane fusion; CCR5 antagonists (e.g. Maraviroc), which 
inhibits viral entry through coreceptor blocking; and integrase strand transfer inhibitors 
(INSTIs) (133). There are however side effects that come with these medical treatments. 
Physicians prescribing ART medicines always try to find a right combination of 
medicines without eliciting too many side effects. However, these drugs may lead to 
some short-term problems such as diarrhea, fatigue or headaches etc., or long-term side 
effects such as lipodystrophy, insulin resistance, and lactic acidosis etc. The short-term 
side effects usually last and fade from days to a month, but people suffering from the 
long-term side effects should consider seeing their doctors periodically (134). Drug 
resistance is another problem. HIV-1-1 mutates during their replications, and the 
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mutations selected by antiretroviral drugs will gradually decrease antiretroviral drugs 
efficacy.  
Immunotherapy 
Immunotherapy is another way of treating HIV-1-1-infected individuals.  
Immunotherapy refers to passively transferring HIV-1-1-specific neutralizing 
antibodies to HIV-1-1 infected patients. However, pre-clinical and clinical trials of 
these therapies all have failed to neutralize viruses (135-137). Therefore 
immunotherapy against HIV-1-1 had been abandoned due to its ineffectiveness for 
many years. However, recent studies taking advantage of novel strategies such as cell-
based immunotherapy successfully suppressed HIV-1-1 in infected humans. On June, 
2015, Caskey M et al. proved that HIV-1-1 viremia can be suppressed in HIV-1-1 
infected humans by passive transfer of a monoclonal antibody named 3BNC117 (138). 
Based on the single-cell-based antibody cloning methods, a new generation of potent 
broadly neutralizing antibodies have been uncovered (139-142), making it possible for 
researchers to produce large amount of broadly neutralizing antibodies (bNAbs). These 
bNAbs have shown promising protection and viremia suppression in humanized mice 
and nonhuman primates (143-145). In addition, a very recent study carried out by 
Nancy Haigwood in 2016 (146), showed that by passively transferring human bNAbs 
as a cocktail of PGT121 and VRC07-523 to infant macaques, SHIV-1 infection can be 
halted with no viral emergence even after CD8+ T cell depletion. This results suggest 
that this human bNAb cocktail immunotherapy can eliminate both viral foci and viral 
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reservoirs at very early stage, making this immunotherapy promising to completely 
eradicate HIV-1-1 and stop HIV-1-1 infection in human infants. 
Vaccine Development against AIDS 
The typhoid vaccine against typhoid bacterium was commercially available after a 
105 year endeavor since pathogen had been discovered. A pertussis vaccine was 
available 89 years after the first reported case. It took us 47 years to develop a vaccine 
against polio and 42 years to develop a vaccine against measles. It therefore seems 
quite understandable that over 35 years of HIV-1-1 vaccine research has not provided 
us with an effective HIV-1-1 vaccine. We must however realize that the time course 
for those released vaccines was reducing, and it only took us 16 years to develop a 
vaccine against the hepatitis B virus. It is predictable that at this age an effective 
vaccine for HIV-1-1 is coming in the foreseeable future.  
 
Traditional vaccine strategies such as subunit, killed or live attenuated vaccines are 
not protective against HIV-1 infection. These vaccines either induce non-bNAbs or 
NAbs but strain specific, so that the low bNAb content is inadequate to have antibody 
protection against HIV-1-1 infection. The first generation HIV-1-1 vaccine, typically 
is represented by the AIDSVAX gp120 subunit vaccine, stimulates antibodies towards 
HIV-1-1 envelope glycoproteins, but proved to be non-neutralizing, and thus failed to 
protect vaccinated individuals from HIV-1 infection (147). The second generation, 
named the STEP vaccine, uses adenovirus serotype 5 virus as backbone vector, to 
26 
carry HIV-1-1 Gag, Pol and Nef genes, expressing these HIV-1 viral proteins. This 
design was predicted to stimulate CD8+ T cell mediated immunity against HIV-1, but 
again showed no effective protection (148, 149). After the above two failed trials, a 
third generation vaccine was created (or we should call it a third efficacy trial, 
because it utilizes a combination of two vaccines described above). This trial, known 
as RV144 (150) was conducted in Thailand. This vaccine strategy is described as 
using a canary pox viral vector carrying HIV-1-1 envelope gene gp120, Gag, and Pol 
to prime the immune response, followed by the AIDSVAX gp120 subunit vaccine to 
boost. The outcome of this trial is not promising: the vaccine efficacy is only 31.2% 
in their modified intention-to-treat study involved 16,395 subjects. In addition, there 
are no significant changes in the degree of viremia or the number of CD4+ T cells. 
This limited protection although not promising, offers insight for further research. 
 
What lessons shall we learn from these vaccine trial failures? First, we understand that 
an effective vaccine should have the potential to stimulate both CD8+ T cell and B cell 
response to multiple epitopes, especially to those highly conserved regions. In addition, 
an effective vaccine that allows T cell response to the common epitopes of different 
variants of the founder virus could inhibit viral immune evasion. Second, the fact that 
bNAbs induced by these conventional vaccines are usually low in number, poor in 
quality, and elicited slow in time reveals that a more reasonable strategy would be to 
create a vaccine that exposes as many conserved epitopes as possible, and also stably 
preserves the native form without denaturing in vivo. In addition, more advanced 
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adjuvants and therapies that can protect bNAbs-producing B cells or rescue the 
damaged or exhausted CD8+ T cells and bNAbs-producing B cells may be necessary 
to work synergistically with vaccines. Third, it will be very wise to understand the HIV-
1-1 envelope structures both in a native form, and in a complex form with potent bNAbs 
binding. Understanding the structures of the HIV-1-1 virion as well as the envelope 
glycoproteins allows us to investigate the epitopes that are targeted by bNAbs, or to 
find out how the conserved regions are shielded by the variable loops and glycans.  
 
There is a remarkable endeavor in recent HIV-1-1 vaccine studies. In 2013, a study 
carried in China designed a novel adjuvant for HIV-1 vaccine delivery (151). Fullerenol 
is self-assembled into virus-sized nanoparticles, and they use this dual-functional nano-
adjuvant to deliver a HIV-1-1 DNA vaccine. Surprisingly, this adjuvant not only shows 
promising adjuvant activity, but also decreases the antigen dosage and immunization 
frequency while maintaining decent immunity levels. What is more, the nano-adjuvant 
promotes effector memory CD8+ T cells in immune response, which has great 
significance in earlier immunity against HIV-1 infection. In November, 2015, a new 
method investigating how HIV-1-1 vaccine induce humoral immunity, termed “systems 
serology”, reported by Chung AW et al. (152), provides us more ideas to understand 
the multi-dimensional relational comparisons in humoral immune response against 
HIV-1-1 vaccine. Furthermore, researchers from Duke University designed a HIV-1 
Env using the novel 3D-printing technique (153). A ligand-free HIV-1-1-Env trimer 
was fixed in its native conformation, and epitopes were analyzed. These antigenicity-
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guided structural designs are promising for a new generation of vaccine antigens. In 
February, 2016, one research team lead by Harvard Medical School and Beth Israel 
Deaconess Medical Center, recombined an HIV-1-1 clade A Env gene into adenovirus 
serotypes 26 and 35 (154). Assessment of the safety and immunogenicity of these two 
adenovirus-vectored-HIV-1 vaccines showed that both vaccines elicited significant 
immune responses without noticeable side effects in monkey model tests. This study 
provides us ideas about designing a desirable HIV-1-1 vaccine delivery system, but 
how long the protection lasts and how well the vaccine protects human after HIV-1 
infection remains unknown. These recent HIV-1 vaccine studies, either focus on the 
adjuvant development, on understanding the humoral response rationale beyond 
vaccination, on choosing a safe and effective antigen delivery vector, or on a structural 
basis to design immunogens with reasonable antigenicity, are very good examples 
representing the promising directions of HIV-1 vaccine development. 
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Chapter 2: Introduction and Objectives 
The structure-based design of HIV-1 vaccine emphasizes the rationale on the structural 
relationship between antigens and antibodies. This method is substantially rational and 
sophisticated in designing immunogens to elicit potent neutralizing antibodies. 
Traditional HIV-1-1 vaccine designs do not pay much attention to the structural 
instability or the potential for antigen denaturing after in vivo antigen delivery, which 
is likely one of the reasons why potent bNAbs cannot be elicited. It is in this context 
that studies focused on structural-based design of HIV-1-1 vaccines have been started 
recently (146, 155). 
 
The envelope glycoprotein of HIV-1-1 is expressed as the gp160 precursor, which is 
then proteolytically cleaved into gp120 and gp41 during maturation in the Golgi 
apparatus (35, 155-158). The two glycoprotein subunits gp120 and gp41 are the sole 
spikes on the surface of HIV-1 virion, so a large number of vaccine designs are based 
on these glycoproteins. Naturally, these two glycoproteins are non-covalently linked 
and are formed as heterodimers, and eventually function as trimers of gp120/gp41 
dimers. Despite the fact that viral envelope protein complexes are well exposed on the 
surface, generation of HIV-1-1-specific neutralizing antibodies are shown to be narrow 
in breadth. As been discussed above, possible reasons may include viral mutation 
resulting in immune evasion. However, recent studies focusing on the HIV-1-1 
envelope trimer structures reveal that another HIV-1-1 immune evasion mechanism 
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may be associated with the rearrangement of the envelope trimer structure during a pre-
fusion to post-fusion transition (159-161). During recent years, the Cyro-EM technique 
has brought the structure of a soluble HIV-1-1 envelope trimer to our horizons (159-
161). This trimer structure was represented in a cleaved state without gp41 MPER 
region and cytoplasmic tail. Later, the crystal structure of this cleaved trimer captured 
by antibodies PGT122 and 35O22 was also established. These findings make blueprints 
for mapping the prevalence and location of effective HIV-1-1 immune recognition.  
 
Over the past 20 years, substantial HIV-1-1 envelope subunits structures have been 
obtained at atomic or near atomic levels. Some of these important findings include the 
structure of the gp120 core and its interaction with CD4 molecule (162), and the 
structure of post-fusion gp41 (163-165). In the context of the trimer, gp120 subunits 
shield most of the gp41 subunit and becomes the most exposed subunit, so that gp120, 
compared to gp41, has been more commonly studies (166)(167)(168)(169)(170). The 
first generation of candidate immunogens was designed based on monomeric gp120 
(146, 164, 165, 171-173). The peptide sequence of gp120 is made up of five conserved 
regions and five variable regions (174-177), the five conserved regions together 
represent the gp120 core. The gp120 core is shielded by highly glycosylated variable 
regions, protecting the core from being neutralized.  
 
Monoclonal antibodies (Mabs) against HIV-1-1 envelope proteins are primarily 
generated from naturally infected human beings or other animals. Among these Mabs, 
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a large number are antibodies that have no neutralizing ability. However, there are some 
potent Mabs which are able to neutralize several primary HIV-1-1 isolates (165, 178, 
179). These neutralizing Mabs include 2F5, 2G12 and lgG1b12. Other Mabs 
particularly interact with the variable loops and are classified as V1/V2/V3 antibodies, 
but they are however only able to neutralize certain epitopes, so their value in vaccine 
development is less promising (178-188). The last group of antibodies directly targets 
the CD4 binding site, called CD4-BS antibodies. These antibodies also provide limited 
neutralizing effect, but they are able to neutralize laboratory-adapted isolates such as 
MN27 and HXBc2 (189, 190) (191). X-ray studies looking at the crystal structures of 
the HIV-1-1 gp120 (191)(192) core region demonstrated that the variable regions in 
two isolates HXBc2 and YU2 share very little accordance in terms of neutralizing 
antibody responses and coreceptor binding. However, the X-ray 3D crystal structures 
of these two isolates are nearly identical (191, 193, 194).  
 
Figure 3 represents the crystal structure of the gp120 core, which is composed of three 
domains: the inner domain, outer domain and bridging sheet (198-201). Moreover, a 
red circle at the junction of three domains indicates the location of the CD4 binding site. 
Recent studies looking at the binding of the structure of gp120 to VRC01, suggests that 
its binding site on gp120 seems to be, to some extent, identical to the CD4 binding site, 
as shown in Figure 4. However, a closer look at their binding sites revealed that VRC01 
majorly binds to the outer domain of gp120, whereas the CD4 binding site consists of 
the junction of the three domains of gp120. These studies provide us with more details 
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about the outer domain of gp120. Compared to the inner domain and bridging sheet, 
the gp120 outer domain is relatively more stable, and is also highly conserved. One idea 
is that by making the outer domain protein as an immunogen, VRC01-like antibodies 
could possibly be induced. A recent study in our lab created two disulfide bonds to 
stabilize the C-N terminal, as well as the 21/22 hairpin in the CD4-bound 
conformation of the gp120 outer domain (195). Immunogenicity of that modified OD 
has been evaluated and showed that OD2 (stabilized with additional two disulfide bonds 
from OD1) compared to OD1, was able to induce and circulate a higher amount of 
neutralizing antibodies in guinea pigs (196).  Based on that study, we have introduced 
an additional S375W mutation to the CD4-bond conformation of outer domain, and 
named it OD3, to further investigate its potential of inducing neutralizing antibodies 
compared to OD1 and OD2. An X-ray crystal study of the gp120-CD4 binding complex 
reveals how the structural conformation of gp120 differs from the unbound state, and a 
thermodynamic study (195) of S375W gp120 binding to sCD4 reveals that there is less 
of an enthalpic and entropic change exhibited upon CD4 binding, which confirms the 
S375W-triggered CD4-bound conformation. The S375W-induced gp120 CD4-bound 
conformation appears to be a valuable conformation for further studies in vaccine 
design. We hope to make the gp120 outer domain a more stable immunogen and bring 
insights for further HIV-1-1 vaccine development.  
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Chapter 3: Materials and Methods 
General Experimental Design 
Figure 5 illustrates the general experimental design in this study. The objective of the 
study is to evaluate the immunogenicity of our designed OD3 immunogen compared to 
OD1 and OD2. Primers were designed to generate the S375W mutation by site-directed 
mutagenesis, and the new gene segment was cloned into the expression vector pET28b. 
Plasmids were transformed into E.coli BL21 (DE3) for protein expression and 
purification. Purified samples were validated by SDS-PAGE, to evaluate immunogens’ 
purity, followed by Western-blot with antibodies targeting different epitopes of the 
gp120 outer domain. Circular dichroism was conducted to confirm the secondary 
structure of the immunogens and to ensure their folding status. Verified immunogens 
were sterilized using the Minisart® 0.20 m non-pyrogenic single-use filter for guinea 
pig immunization. A 63-day immunization protocol was followed. Guinea pig serum 
was collected at different time points for immunogenicity studies. HIV-1-1 
pseudotyped viruses were generated by transfection of viral envelope plasmid, a CMV 
packaging plasmid and a luciferase plasmid into 293T cells. These pseudotyped viruses 
were utilized in the viral neutralizing assay. 
Virus Strains 
Viruses used for the neutralization assay were pseudotyped HIV-1-1 viruses produced 
by transfection of 293T cells with three plasmids: a plasmid carrying luciferase 
34 
expressing gene (pHIV-1-luc), a plasmid packaging HIV-1 Gag and Pol gene (pCMV 
Gag-Pol) and plasmids expressing the HIV-1-1 envelope proteins of isolate variants 
(pSVIIIenv) (197, 198). Transfection of these three plasmid produces luciferase-
expressing HIV-1-1 isolates in 293T cells after three days of incubation. 
Molecular Modeling and Designing of OD3 
The glycoprotein-antibody complex, HIV-1-1 subtype B strain gp120 and the VRC01 
monoclonal antibody complex were used as structural models to study and predict the 
gp120 structure of the HIV-1-1 subtype C strain 1084i. Based on a paper published 
from our lab (199), we designed the OD1 and OD2 immunogens using the software 
Discovery Studio Client 3.5 (Accelrys, San Diego, CA). OD1 is the wildtype gp120 
outer domain and OD2 refers to the disulfide bond induced gp120 outer domain. OD3, 
used in this study, was modified from the OD2 protein with a serine to tryptophan 
mutation at location 375. This S375W mutation was first assessed in a full length gp120 
in 2002 (200). The S375W mutation resulted a tryptophan indole ring occupying the 
Phe 43 cavity, which favors a gp120 conformation close to the CD4-bound state, which 
was better recognized by either CD4 or CD4-induced antibodies, and less favorable to 
CD4-binding-site antibodies. Considering the fact that S375 is located in the outer 
domain of gp120, we introduced the S375W mutation and designed OD3 to test its 
immunogenicity. All structural-based modification designs were performed on the 
platform of Discovery Studio Client. We numbered the protein sequences of OD1, OD2, 
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and OD3 based on the reference of the envelope sequence of the HIV-1-1 prototypic 
HXBc2 strain (201).  
Cloning and Expression of OD3 
The gene design of OD3 was based on our previous work on OD1 and OD2, and all the 
genes were designed using the HIV-1-1 subtype C strain 1084i (201). OD1 and OD2 
were synthesized by GenScript®. Basically, the wildtype OD1 has 214 amino acids, 
from 246 to 460 of gp120, and the design of OD2 was modified from OD1 to introduce 
two disulfide bonds (4 cysteine substitutions were introduced at the amino acid 
locations 257, 370, 425, and 472). In the design of OD3, a serine at the amino acid 
location 375 was mutated to tryptophan (S375W) from OD2 by mutagenesis. To be 
specific, the forward primer (5’-CGT TGC ATC ACC ATG CAC TGG TTC AAC TGC 
CGT GGT-3’) and the reverse primer (5’-ACC ACG GCA GTT GAA CCA GTG CAT 
GGT GAT GCA CAG-3’) were synthesized by GeneScript®. Primers were used in 
site-directed mutagenesis and OD3 was cloned into the vector pET28b. All the genes 
were designed with a 6xHis-tag at the N-terminus for the future purpose of protein 
purification. 
 
The designed OD3 gene was cloned along with OD1 and OD2 into the pET28b 
expression vector (Novagen), and E.coli BL21 (DE3) was used as the protein 
expression system. Sequence confirmation was conducted by Operon® to make sure 
the open reading frame, the designed mutation as well as the N-terminal 6x histidine 
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tag were correct and present. Three genes in pET28b were transformed into E.coli BL21 
(DE3) competent cells. 60 L competent cells were mixed with 100ng plasmid of each 
gene on ice for 10 minutes in a 1.5 mL Eppendorf tube. The tubes with plasmid and 
cells mixture were then incubated in a 42°C water bath for 2 minutes. Tubes were then 
placed on ice following heat shock for 5 minutes. 0.5 mL of LB Broth (Lennox) media 
with no antibiotics was added into each tube containing the OD1, OD2, and OD3 
plasmid transformed cells, and were then incubated in the 37 °C shaker at 200 rpm for 
20 minutes. 50 L of cell culture suspension were then taken from each tube, and were 
spread on LB agar plates supplemented with 50 mg/L kanamycin. After 14 hours of 
incubation at 37°, single colonies from each of the 3 plates were picked up and grown 
in 3 mL LB media with 50 mg/L kanamycin in the 37 °C shaker at 250 rpm until the 
optical density reached between 0.4 and 0.6 at 600 nm. The cells were induced by 
adding 1mM isopropyl-D-thiogalactopyranoside (IPTG) at a final concentration of 1 
mM, and continuously grown for another 3.5 hours. All the bacterial culture was finally 
harvested and collected by centrifugation at 6000 G for 15 minutes. The cell pellets 
were washed once with STE buffer containing 100 mM NaCl, 10 mM pH 7.5 Tris, and 
1 mM Ethylenedinitrilo tetraacetic acid disodium salt (EDTA). Cells were suspended 
in STE+ buffer (100 mM NaCl, 10 mM pH 7.5 Tris, 1 mM EDTA, 0.5% NP40, 100 
mg/L lysozyme, and protease inhibitors), and incubated on ice for 20 minutes. Cells 
were then disrupted by sonication and were centrifuged at 14000 rpm at 4°C for 10 
minutes. Both supernatant and cell debris were collected to determine whether the 
protein of interest was in supernatant or insoluble fraction. An SDS-PAGE test followed 
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by Coomassie blue staining and anti-6xHis western blot were conducted to determine 
the existence of our protein of interest. We found that the majority of the recombinant 
protein existed as inclusion bodies. The transformed strain E.coli BL21 (DE3) 
containing each OD1, OD2, OD3 plasmid were made into glycerol stocks for further 
experiments. 
Immunogen Purification  
OD1, OD2 and OD3 protein expression began by the inoculation from the glycerol 
stock of E.coli BL21 (DE3) containing each OD1, OD2, OD3 plasmid into 3 mL LB 
media with 50 mg/L kanamycin. 3 mL bacterial culture were then added into 300 mL 
LB (1:100) with 50 mg/L kanamycin, then were incubated, induced with IPTG, 
collected, washed, and lysed using the same method mentioned above. To purify the 
recombinant protein as inclusion bodies, 4 subsequent washes were performed to 
gradually increase the purity of our protein of interest. First, they were washed with 1x 
PBS+0.1% SDS, then with 1x PBS+1% NP-40, then with 1x PBS+1% TritonX-100 
and finally with 1x PBS+2 M urea. Short periods of sonication impulse were introduced 
during the washes to better diffuse the inclusion bodies. The insoluble fraction after 4 
washes was finally solubilized in 3 mL solubilization buffer (8 M urea, 50 mM NaCl, 
20 mM Tris (pH=7.5), and 5 mM Dithiothreitol (DTT) at 4°C for 30 minutes. The 
solubilized sample was then transferred into a dialysis cassette (Slide-A-LyzerTM G2, 
Thermo Scientific). Our sample was then renatured by successive dialysis against the 
refolding buffer at 4°C (pH=7.5 20 mM Tris, 400 mM L-Arginine, 1 mM EDTA, 5% 
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glycerol, 0.4 mM Glutathione (GSH) and 1 mM Glutathione disulfide (GSSG) 
containing 4 M, 2 M, 1M, 0M urea), for 2 hours, 8 hours, 8 hours, and 24 hours 
respectively. The refolded protein samples then underwent an affinity purification 
known as immobilized metal affinity chromatography. Ni-NTA resin beads (Thermo 
Scientific) were used to further purify the protein. Protein purity was measured by 
Coomassie blue staining and Western blot analysis. Concentration of the protein 
samples was determined by a BCA protein kit (Pierce). Purified and renatured protein 
samples were then used for further characterization. 
Immunoblotting  
Purified protein samples were loaded into a 10% SDS-denaturing gel along with 
negative (bovine serum albumin (BSA)) or positive (recombinant gp120) controls. The 
gels were run for 75 minutes at 60 volts. Nitrocellulose membrane transfer followed the 
SDS-PAGE (204). After 30 minutes blocking with 5% non-fat dry milk in phosphate-
buffered saline (PBS), nitrocellulose membranes were incubated for one hour at room 
temperature with primary antibodies. Following six washing steps (five minutes each) 
with PBS+0.1% Tween-20, horse radish peroxidase (HRP) conjugated secondary 
antibodies were incubated with membranes for 30 minutes at room temperature. Six 
washes were followed as explained previously. The outcome of antigen-antibody 
binding was detected either using SuperSignal West Dura Extended Duration Substrate 
kit (Pierce) or using a BioRad ChemiDoc (LiCor Inc., Lincoln, NE) (205).  
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Secondary Structure Characterization 
A desalting process was performed prior to the circular dichroism (CD) characterization. 
A desalting column (zebaTM Spin Desalting Columns, 7K MWCO, 5 mL) was used to 
remove L-arginine from the protein solution to avoid noisy signals. The instrument used 
for CD is a Jasco J-815, which is equipped with a cell compartment with a Peltier-type 
thermostat and a water circulator. The acquisition and data analysis are also from Jasco.  
Data was recorded using either a 1 mm cell-path 300 L quartz cuvet or a 0.1 mm 
15000 L circular quartz cuvet at 20°C. The data was exported in XY asci format and 
analyzed with the program CD-Pro located at the DichroWeb site from the University 
of London, for the purpose of estimation of the secondary structure of the protein. The 
data was analyzed in the raw machine units (millidegrees) with the same resolution as 
the acquired data (1 data point per nanometer). The cell path, average molecular weight 
and protein concentration were provided prior to the fitting, which was carried out using 
the various models available (CONTINLL and SELCON3 yielded the lowest RMSD 
values) until a satisfactory fit was obtained. The results were imported into Sigmaplot 
(SPSS) which was used to plot the data along with the simulated secondary structure 
spectrum. Our three protein samples were measured at the same concentration of 0.35 
g/ml, solubilized in buffer containing 20mmTris-HCl and 2mm EDTA at pH=8.0,and 
the recording pathlength is 0.01 cm. 
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Guinea Pig Immunization 
The standard 63-day immunization protocol of Cocalico Biologicals, Inc. (CBI) for 
guinea pigs was followed. 16 guinea pigs were assigned evenly into 4 groups: 
inoculated with OD1, OD2, OD3 or adjuvant only (Complete Freund’s Adjuvant or 
Incomplete Freund’s Adjuvant). Three booster injections were carried following the 
first injection. Blood samples were collected from all guinea pigs on Day 0, prior to 
immunization as prebleed samples; on day 35 as test bleed samples after 2 boosts on 
day 14 and day 21; and on day 63 as exsanguination samples following the third boost 
on day 49. Blood samples collected (pre-bleeds, test bleeds and final bleeds) were used 
in antibody testing, ELISA and neutralization assays. All animal experiments were 
performed according to the protocol approved by the IACUC of CBI (Reamstown, PA).  
ELISA 
Flat-bottom, with low evaporation lid 96-well plates (FalconTM) were coated with 200 
ng per well of test protein (OD1, OD2 and OD3) diluted in coating buffer (15 mM 
Na2CO3 and 35mM NaHCO3, pH 9.6). Prior to blocking, plates were washed with 
phosphate buffered saline with 0.1% Tween-20 (PBS-T, Sigma-Aldrich) 3 times. Plates 
were blocked with 200 μL/well blocking buffer (PBS-T with 5% milk) at room 
temperature for 1 hour. After 3 washes with PBS-T, 100 μL/well of guinea pig sera 
diluted in PBS-T at different ratios was added and incubated at room temperature for 2 
hours. Plates were washed 5 times prior to the addition of 100 μL/well of HRP-
conjugated goat anti-guinea pig IgG secondary antibody (Jackson ImmunoResearch 
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Laboratories Inc.), and incubated at room temperature for 2 hours. Plates were washed 
5 times, and 100 μL/well SureBlue ReserveTM TMB substrate (KPL) was added and 
incubated for 1 min in the dark. 100 μL/well of 1 M HCl was added to stop the reaction. 
Absorbance data was collected at 450 nm using an ELX 800 UV universal microplate 
reader (Bio-Tek Instruments). 
Generation and Titration of Viral Stocks 
HIV-1-1 isolates used for neutralization assay are pseudotyped HIV-1-1 viruses 
produced by transfection of 293T cells with three plasmids: pHIV-1-luc, pCMV Gag-
Pol, and pSVIIIenv of different isolates, as mentioned above. Transfection of these 
three plasmid produces luciferase-expressing HIV-1-1 isolates in 293T cells after a 
three day incubation period. Transfected 293T cells were grown at 37°C with 5% CO2, 
and maintained in DMEM medium with 584 mg/L L-Glutamine (Gibco), supplemented 
with 10% FBS and 1X penicillin-streptomycin. Twenty-four hours prior to transfection, 
1.5x106 cells were plated in 10 cm dishes. Cells were transfected by adding 6µg of 
replication-deficient HIV-1 luciferase plasmid pHIV-1-luc, 2 g HIV-1-1 envelope 
construct pSVIIIenv-Yu2/1084i/89.6/JRFL/HXBc2/ADA, and 2 µL CMV backbone 
plasmid diluted in 1 mL unsupplemented DMEM. Polyethylenimine (PEI) was the 
transfection reagent used in this experiment. Cell supernatants were collected at 72 
hours post-transfection, and passed through a 0.45 µM syringe tip filter. The amount of 
virus in the supernatants were measured by reverse transcriptase (RT) assay (202).  
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Virus Neutralization Assay 
The neutralization assay was based on methods previously described in our published 
paper (199). TZM-bl cells were incubated at 37°C supplement with 5% CO2, and 
maintained in DMEM medium containing 4.5 g/L D-glucose and 584 mg/L L-
Glutamine, supplemented with 10% FBS and 1X penicillin-streptomycin. One day prior 
to the assay, cells for infections were seeded at 0.6x104 per well in 96-well plates, flat-
bottom, black-sided plates (Grenier Bio-One). In another separate 96-well plate, heat-
inactivated guinea pig serum was serially diluted to a final volume of 100 μL of cell 
growth media, mixed with 2000 RT units of pseudotyped HIV-1-1 in 50 μL cell growth 
media. The virus and cell mixtures were incubated for 1 hour at 37°C with 5% CO2, 
and during this incubation, the TZM-bl growth media was replaced with 50 μL media 
containing 160 μg/mL DEAE-Dextran (Sigma-Aldrich) (40 μg/mL final concentration). 
The serum-virus mixture was added to cells and incubated at 37°C for 60 hrs. The 
luciferase assay system (Promega) was used to detect Tat-inducible luciferase. 
Luminescence was measured on a Veritas luminometer (Turner Biosystems). Percent 
neutralization was determined using the following equation: (1 – ((test well – cell 
control well) / (virus control well – cell control well))) x 100 (203).  
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Chapter 4: Results and Discussions 
Structural Based Immunogen Design 
The outer domain (OD) of HIV-1-1 gp120 envelope glycoprotein contains epitopes for 
CD4-BS antibodies due to the biological nature of its interactions with CD4 molecule. 
Some CD4-BS bNAbs neutralize 90% of HIV-1-1 isolates, such as VRC01. 
Considering the fact that the outer domain is relatively more stable than other domains 
of gp120, the outer domain has been considered to be a potential HIV-1-1 vaccine 
immunogen candidate. However, efforts to elicit bNAbs with the outer domain have 
not been successful. Studies of the outer domain crystal structures revealed that the 
when the outer domain only was represented in a truncated form, the protein structure 
does not remain consistent with the native form when the outer domain was presented 
within gp120 (204)(195) (205). To be more specific, the C and N terminal of OD1 
(refers to the truncated outer domain without any structural modifications) are more 
widely open, and the 20-21 hairpin is less closed to the outer domain core and the 
structure around the Phe 43 cavity does not exactly resemble the native form. Here, we 
based our design the OD2 structure and introduced a S375W mutation to further stable 
the outer domain. In summary, an OD3 immunogen design involves the following 
strategies: 1) keeping the outer domain core structure by removing all the variable loops; 
2) introducing two disulfide bonds to stabilize the C-N termini and the β20-21 hairpin; 
3) introducing an S375W mutation to have the indole ring from tryptophan filled into 
the Phe 43 cavity.  
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Figure 6 represents details of superimposed structures of the OD3 compared to OD1, 
and Figure 7 shows the designed structures of three proteins, and the amino acid 
locations of the mutations for the disulfide bonds and S375W. The outer domain 
designed in this way is predicted to be more favorable to CD4-BS bNAbs binding and 
thus is more promising to recruit potent bNAbs such as VRC01-like antibodies. The 
highly conserved outer domain, as mentioned previously, has more antigenic 
importance in eliciting effective antibodies than the variable loops. In our design, the 
variable loops have been completely removed so that the outer domain core is free from 
variable loop masking and glycan shielding. Furthermore, the S375W mutation is 
predicted to further stabilize the outer domain into a CD4-bound state, which is more 
vulnerable to CD4-BS antibody neutralizing. This taken together may explain why our 
OD3 design is able to induce higher level of potent neutralizing antibodies compared 
to OD1 and OD2, which will be further discussed. 
Generation and Validation of Immunogens 
The designed OD3 gene was cloned into a bacterial vector pET28b and expressed in 
the E. coli strain BL21 (DE3). The strain BL21 is an E. coli K12 derivative which 
contains mutations in both the thioredoxin reductase and glutathione reductase genes 
that allows an intracellular environment for proper disulfide bond formation. OD3 was 
expressed along with OD1 and OD2 in this strain and was induced by IPTG for optimal 
recombinant protein expression. Purification of these three immunogens was achieved 
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by washing inclusion bodies followed by protein refolding dialysis and 6x His-tag metal 
affinity chromatography purification. A SDS-PAGE gel, shown in Figure 8, reflects 
the size and purity of three proteins. The clear bands around the molecular weight of 25 
kDa marker suggested the recombinant proteins (weight 22.2 kDa) were detected at 
correct size. Proteins were concentrated by Pierce™ Protein Concentrators PES, 10K 
MWCO to a range from 0.2-2 g/l for experiments. 
  
Purified proteins were further validated by immunoblotting, as shown in Figure 9. To 
be more specific, the CD4-BS monoclonal antibodies F105, VRC01 and b12 
demonstrated binding affinity to all three proteins. In addition, polyclonal antibodies 
including patient sera and a commercially available anti-gp120 (abcam Inc. ab53840) 
all showed distinct bands responding to the immunogens. Last, a CD4 induced 
monoclonal antibody 17b, also showed binding activity to all three immunogens but 
was relatively weaker than other antibodies. 
Secondary Structure Verification 
Circular dichroism (CD) is an excellent method of rapid protein secondary structure 
determination. Typically, protein samples with α-helixes will show negative ellipticity 
bands at 222 nm and 208 nm and a positive band at 193 nm (206), whereas protein 
samples containing β-sheets have negative bands at 218 nm and positive bands at 195 
nm (207). Proteins with disordered turns have very low ellipticity above 210 nm and 
negative bands near 195 nm (208). Figure 10 shows the secondary structure analytical 
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results of our three outer domain immunogens (OD1, OD2 and OD3) obtained through 
circular dichroism. The data was analyzed by software CDSSTR and is summarized in 
Table 1. The analytical results showed that: 1) OD2 is different from OD1 with two 
disulfide bonds, and this difference is reflected by the increase in the OD2 positive 
ellipticity absorbance at 193nm and same absorbance at 195nm. This result suggested 
that the two disulfide bonds help the protein organize some unordered turns into well-
ordered α-helix-like structures, without disrupting β-sheets. 2) OD3 is different from 
OD2 with a S375W mutation, which stabilizes the outer domain to a CD4-bound state. 
In the Figure 10, an OD3 curve not only showed positive ellipticity absorbance at both 
193nm and 195nm, but also showed an increase in the negative band at 208nm, 218 nm 
and 222 nm, suggesting more unordered peptide structures transferred to α-helixes, 
helixβ-sheets structures and ordered turns. These data provided us an idea that our 
S375W mutation in outer domain is very likely to stabilize the immunogen by making 
the outer domain secondary structure more organized.   
 
In the total amino acid sequence, there are 26 amino acids organized in alpha helices 
and 70 in beta sheets, out of a total of 195. Thus the composition as far as secondary 
structure is predicted to be 13 % alpha helical and 36% beta sheet. This is in good 
agreement with the observed results for the beta sheets. Note that type 1 helix which is 
the most common, is usually more accurate, yielding 13-14%, in agreement with the 
predicted secondary structure. 
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Immunogenicity of Designed Immunogens in Guinea Pigs  
The purified, validated protein immunogen samples were then utilized in immunization 
studies. We ordered 16 guinea pigs and evenly divided them into 4 groups, each of 
those was inoculated with our three immunogens respectively, and one group was 
inoculated with adjuvant only as negative control. The Freund’s adjuvant system 
(CFA/IFA) was used for this immunization test. Figure 11 shows the basic protocol 
and timeline of the immunization carried out in this study. Blood samples were 
collected at three time points: at day 0, which is referred to as the pre-bleed serum 
samples used as a negative control; at day 35, which is referred to as the test bleed 
serum samples, and at day 63, the last day, which is referred to as the final bleed serum 
samples. All inoculations, boosts, and blood sample collection was conducted by 
Cocalico Biologicals, Inc. in Reamstown, PA.  Serum samples of all guinea pigs were 
shipped overnight in dry ice to us and were properly stored at -80°C. These serum 
samples were used in immunogenicity studies including Western-blotting, ELISA and 
virus-serum neutralization assay.  
Antibody Specificity Validation 
Immunogenicity of our designed immunogens was first evaluated by Western-blotting 
assay to see whether there were antigen specific antibodies elicited in the immunized 
guinea pigs. The data from these experiments is shown in the Figure 12. We blotted 
each antigen with the final bleed serum collected from all groups. All sample groups 
inoculated with their assigned antigens (OD1, OD2 and OD3) showed related binding 
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activity. And the clear bands indicated our purified antigens remained stable in the 
storage condition of -80°C. In addition, all groups inoculated with any antigens (except 
for the group immunized with adjuvant only) showed that their serum not only contains 
antibodies against gp120 outer domain. Instead, as we predicted, no guinea pigs elicited 
outer domain specific antibodies when were just inoculated with adjuvant (only some 
results are shown here). These results proved the inoculation of our designed 
immunogens successfully induced outer domain specific antibodies. 
Antibody Titer Determination 
In order to further evaluate the immunogenicity of our designed antigens, typically, to 
compare the immunogenicity differences between the three antigens, an ELISA assay 
was conducted and the results compared the total outer domain-specific antibodies 
induced by three antigens in guinea pigs. As previously mentioned, “pre-bleed”, “test 
bleed” and “final bleed” refers to serum samples collected from day 0, day 35 and day 
63 respectively. Figure 13, shows the data combining ELISA panels from the pre-bleed, 
test bleed, and final bleed of four groups. The three panels on the Y-axis represent the 
pre-bleed, test bleed and final bleed antibody titers compared in four groups, whereas 
the four panels on the X-axis represent the antibody titers in four groups immunized 
with OD1, OD2, OD3, ADJ (adjuvant only). In general, before inoculation, of all 
groups, no guinea pig individuals contain outer domain specific antibodies, reflected 
by the antibody titers of pre-bleed panels, which were all negative background. 
However, after antigen inoculation and two boosts followed at day 14 and day 21, test 
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bleed serum from day 35 showed evidence of outer domain specific antibody generation. 
There were no significant individual difference among all 12 guinea pigs in group one, 
two and three, except for one case in the OD3-immunized group, in which one guinea 
pig seemed to generate lower titers of outer domain specific antibodies. The difference 
is significant at the serum dilution ratio of 1:100 to 1:2500. However, when we looked 
at the final bleed panels, we found that although the individual differences are still not 
significant in all groups, the guinea pig in OD3-immunized group who showed a lower 
antibody titer at day 35 recovered with higher amounts of antibody, making the 
individual difference less significant at day 63 than day 35. This increase in antibody 
titer is supported from the third boost in day 49, reflected in the OD3 immunized test 
bleed and final bleed panels, in which the antibody titers (absorbance at 450nm) 
increased from 1.5 to 2.2. Moreover, antibody titers are slightly increased in guinea 
pigs at day 63 than that at day 35, although the difference in OD3 immunized group is 
less significant. This result suggests that the third antigen boost provided some limited 
help in recruiting antigen-specific antibodies. Lastly, no HIV-1-1 outer domain specific 
antibodies were found in all adjuvant immunized guinea pigs. It is therefore confirmed 
again that antibodies found in the immunized guinea pigs were specifically induced by 
the immunogens of the outer domains (OD1, OD2 and OD3).   
 
Another important analysis is to evaluate the antigenic differences among these three 
immunogens, and the differences can be more easily assessed in Figure 14, which 
reorganizes the ELISA data in another way, represented as bar charts. From this figure 
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we can tell that all three antigens induced a significant amount of antibodies compared 
to adjuvant immunized groups. This figure however cannot detect any significant 
differences between the OD1 and OD2 groups, but there is a significant difference when 
comparing the antibody titers between OD3 and the other two groups, from which we 
found that at 1:100 serum dilution ratio, the antibody titers of OD3-immunized groups, 
reflected by absorbance at 450 nm, showed an average value of 2.87 in the test bleed 
panel and 3.06 in the final bleed panel. Similar results were obtained at a lower serum 
dilution ratio of 1:500 and 1:2500, suggesting that this assay has some value to 
distinguish the antigenic differences between the three antigens, reflecting a higher 
amount of the total antigen specific antibody titers in the OD3 immunized group. 
 
Taken together, these results reveal that: 1) there are very small individual differences 
in the antibodies elicited between the four guinea pigs in the same groups; 2) there is 
some effect of inducing a higher amount of antigen-specific antibodies from the third 
boost in OD1 and OD2 group, but no significant increase in OD3 group; 3) there is no 
significant difference in the total antigen-specific antibodies between the OD1 and OD2 
groups, but antigen specific antibody titers are significantly higher in OD3 groups. 
However, there is a need to further investigate the antigenicity difference of the three 
antigens and thus the virus-serum neutralization assay is needed to compare the 
differences of their antigen-specific broad neutralizing antibody titers. 
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Serum Neutralization against Diverse Viral Strains 
In order to evaluate the immune response to the antigens resulting in antigen-specific 
HIV-1-1 neutralizing antibodies, we investigated the neutralizing abilities of serum 
from guinea pigs in all groups. Six HIV-1-1 isolates from subtype B and C including 
five primary isolates YU2, ADA, 89.6, 1084i, JRFL and one lab-adapted strain HX-
Bc2 were evaluated in this assay. Figure 15 compares the neutralizing activity of the 
pre-bleed serum, test bleed serum and final bleed serum among the three antigens. Each 
panel line on the X-axis represents one HIV-1-1 isolate involved in the neutralizing 
experiment. Clearly, the figure points to a conclusion that, compared to the serum 
collected in day 0, all antigen-immunized guinea pigs at day 35 and day 63 generated 
neutralizing antibodies against all six HIV-1-1 isolates. However, the neutralizing 
activities differ among the three antigen-immunized groups. To be specific, for all 
panels, OD2 and OD3 are more capable of inducing neutralizing antibodies against all 
six HIV-1-1 isolates than OD1. Overall, there is no significant percentage of 
neutralization difference between the test bleed and final bleed serum in all antigen-
immunized groups, for any virus isolates. The only exception was the isolate 89.6 
neutralized by OD3 serum, in which the final bleed serum remains stronger protection 
at all four serum dilution ratio. Previous ELISA data showing no significant difference 
in the total antibody titer in all groups may explain the insignificance of neutralizing 
antibody titers between the test and final bleed sera in these groups. The exception of 
89.6 being neutralized at a higher percentage by OD3 final bleed serum than test bleed 
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serum may be explained by the fact that 89.6 isolate is somehow more sensitive for 
serum neutralizing when the total antigen specific antibody titers are at a higher amount. 
The fact that overall there is no significant difference between test bleed and final bleed 
serum neutralizing activities suggests that during the guinea pig immune response, 
though the total antigen-specific antibodies were continuously recruited after the third 
boost, the level of broad neutralizing antigen-specific antibodies remained the same, 
indicating either there is an antigenic limit for these antigens to induce neutralizing 
antibodies, or the total neutralizing antibodies are all induced at day 35 so that there are 
few remaining neutralizing antibodies induced by the third boost.  
 
To compare the biological activity of the neutralizing antibodies in guinea pig serum 
induced by our designed antigen OD3, to the wild type OD1 and two-disulfide-bond 
OD2, the original data is reorganized into Figure 16. Each panel on the X-axis again 
represents one HIV-1-1 isolate neutralization, but each of the 6 panels on the Y-axis 
are serum from day 0, day 35 or day 63. As negative controls, pre-bleed sera is not 
supposed to have neutralizing antibodies, which is clearly represented by the day 0 
panels, showing that there are no HIV-1-1 neutralizing antibodies that exist before 
antigen inoculation. Furthermore, serum from day 35 and day 63 show all three antigens 
elicited neutralizing antibodies, but the neutralizing activities are different. Generally, 
OD1 induced less neutralizing antibodies, and the percentage of viruses neutralized by 
OD1-immunized serum is only slightly larger than that of adjuvant alone. Although this 
is not necessarily true in the cases of YU2 and JRFL, the overall performance of OD1 
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was not satisfactory. Serum from OD2-immunized guinea pigs showed significantly 
stronger protection than the OD1 group. In Figure 16 we show that OD2-immunized 
sera from both day 35 and day 63 neutralized a higher percentage of viruses in all HIV-
1-1 isolates than OD1. Furthermore, OD2-immunized sera from day 63 reduced 1084i 
and JRFL viral infection by 81% and 79% respectively, compared to the OD1 group, 
which reduced infection by 62% and 43% respectively. These results suggest that the 
disulfide bonds formation, to some extent stabilized the immunogen to become more 
immunogenic in terms of inducing neutralizing antibodies. Moreover, serum from the 
OD3-immunized group contains more neutralizing antibodies than the OD2 group. The 
data in Figure 16 shows that OD3-induced neutralizing antibodies were more potent 
than OD2 in neutralizing five of the six HIV-1-1 isolates: 89.6, ADA, HXBc2, YU2 
and 1084i. In the case of the HIV-1-1 isolate JRFL although there is no significant 
difference between OD2 and OD3 in antibody titers, the percentages of viral reduction 
were quite comparable. 
 
Finally, data in Figure 17 compares the neutralizing activity of OD3-immunized serum 
in six HIV-1-1 isolates and one non-HIV-1-1 virus strain AMLV (Amphotropic Murine 
Leukemia Virus). The non-HIV-1-1 AMLV served as a good negative control, 
reflecting that the neutralizing antibodies are HIV-1-1 specific since they did not 
neutralize AMLV. Among these HIV-1-1 isolates, the dual-tropic 89.6 is the most 
vulnerable strain to OD3-induced antibody neutralization, followed by the lab-adapted 
strain HXBc2. On the other hand, YU2, and ADA are relatively more challenging for 
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neutralization. However, all of these isolates are neutralized by OD3-immunized serum 
at 70% or higher at the 1:20 serum dilution ratio, suggesting OD3 to be a valuable 
immunogen for further characterization. 
 
Taken together, the virus neutralization results showed that the disulfide-stabilized 
OD2 immunogen had better neutralization activities than the wild-type outer domain 
(OD1), and the S375W-stablized OD3 had the best neutralizing activity against various 
HIV-1-1 isolates. The S375W mutation serves a role in better stabilizing the 
immunogen in a way that is favorable to elicit potent neutralizing antibodies against 
heterologous HIV-1-1 isolates. This example of design using structural information 
demonstrated that structural-based modification for immunogen stabilization is a better 
strategy for improving vaccine immunogen design. 
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Chapter 5: Summary 
Our designed OD3 was purified at an optimal purity, and validated by Western blots. 
The secondary structures of all three immunogens were evaluated and the designed 
OD3 was found to be more organized in the secondary structure. The immunogenicity 
of the OD3 immunogen designed with the S375W mutation and two disulfide bonds 
has been evaluated clearly in guinea pigs. Compared to OD1 and OD2, OD3 induces a 
higher level of both total antigen-specific antibodies and neutralizing antigen-specific 
antibodies. Our experimental results suggest that a structural-based vaccine design is a 
better strategy compared to conventional vaccine designs using killed or subunit 
particles without any structural modifications. Due to the breadth limitedness of this 
project, there are some imperfections in applying our designed OD3 vaccine. First, 
although OD3 induces both total and neutralizing antigen-specific antibodies higher 
than OD1 and OD2, and even though these antibodies are capable of neutralizing 
diverse HIV-1-1 isolates, these antibodies did not reach 100% neutralization against 
any HIV-1-1 isolate at the lowest serum dilution ratio. Second, although the ELISA 
assay showed that there is a significant amount of antigen-specific antibodies even 
when the serum was diluted to 1:2500, our serum lost its neutralizing activity at a serum 
dilution lower than 1:180. Taken together, this outer domain stabilization largely 
improved the outer domain’s immunogenicity compared to the native wild type, 
however more efforts are needed to make this immunogen to become applicable. Other 
structural-based immunogen designs may work synergistically with our strategy. For 
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example, structural-based designs targeting the MPER domain of gp41 may work 
together with the outer domain in inducing potent broad neutralizing antibodies. Also, 
novel adjuvants and vaccine delivery methods may help to improve the 
immunogenicity of the structural-based designed vaccines and finally provide us a 
potent vaccine that is capable of inducing both T cell and humoral immunity to 
eliminate HIV-1-1. 
 
 
 
 
Tables and Figures 
Table 1: Compositions of the secondary structures in OD1, OD2 and OD3. [Back to 
text] 
 
 
OD1 (%) OD2 (%) OD3 (%)
Helix1 14 16 17
Helix2 8 9 8
Strand1 21 21 21
Strand2 14 15 17
Turns 22 23 25
Unordered 21 16 12
Secondary
Structures
Immunogens
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Figure 1: Diagram of an HIV-1 virion structure. (Adapted from the website of 
Wikipedia, the free encyclopedia) [Back to text] 
 
 
Figure 2: Schematic presentation of HIV-1-1 genomic organization. (Adapted from 
HIV-1 Sequence Compendium 2015). [Back to text] 
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Figure 3: The gp120 core structure: Inner Domain (ID), Outer Domain (OD) and 
Bridging Sheet (BS). [Back to text] 
 
Notes: The CD4-binding site (CD4-BS) is located at the junction of three domains 
indicated by the red circle. The picture was adapted from Kwong et al. (Nature. 1998 
Jun 18; 393(6686):648-59). 
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Figure 4: Superimposed CD4 receptor and VRC01 antibody bindings to the gp120 of 
HIV-1-1. [Back to text] 
 
Notes: The gp120 is depicted in a surface model. The gp120 inner domain (ID) is in 
gray, and outer domain (OD) in cyan. The HIV-1 receptor CD4 (color yellow) and 
neutralizing antibody VRC01 are depicted in ribbon strips (colored red for the heavy-
chain (HC), magenta for the Light-chain (LC)). 
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Figure 5: Schematic presentation of the general experimental design. P-OD2, plasmid 
OD2; P-OD3, plasmid_OD3. [Back to text] 
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Figure 6: Superimposed OD3 (color cyan) and the wild-type outer domain OD1 from 
HIV-1-1 strain HXBc2, PDB # 4I3S, color purple) structure. [Back to text] 
 
Notes: 4I3S refers to the sequence of HXBc2 outer domain. Od3_1084i refers to the 
OD3 gene mutated from 1084i outer domain. Dis-1: disulfide bond-1, was created to 
stabilize the C-N termini, and Dis-2: disulfide bond-2, was created to stabilize the 
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beta 20-21 hairpin. The OD1 structure is from published data on the HXBc2 outer 
domain, and OD3 structure was modeled in Discovery Studio Client 3.5 based on the 
outer domain sequence of 1084i isolate. [Back to text] 
 
Figure 7: 3D modelling of the three designed immunogens and their amino acid 
changes. [Back to text] 
 
Notes: The outer domain was cut-off from the position 254 of full length gp120 
molecule, which corresponds to the position 1 of the outer-domain numbering in this 
diagram. Based on the full length sequence of gp120 standard numbering system 
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(209), these mutations in this diagram are also indicated as follows: Dis 1: Dis 1: 
disulfide bond-1, T/C257-G/C472 (T/C4-GC185 in this table); Dis 2: disulfide bond-
2, E/C370-N/C425 (E/C97-N/C139); S375W (S/W102). 
Figure 8: Antigen purification represented by SDS-PAGE. [Back to text] 
 
 
Figure 9: Characterization of the three immunogens by Western blot. [Back to text] 
 
Notes: After SDS-PAGE and membrane transfer, protein samples of OD1, OD2, OD3 
and BSA were probed with pooled serum from HIV-1-1 positive patients, anti-gp120 
polyclonal antibody, CD4-BS monoclonal antibodies VRC01, F105, b12 or b12, and 
CD4-induced monoclonal antibody 17b. 
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Figure 10: Circular dichroism spectra of three immunogens with representative 
secondary structures. [Back to text] 
 
Notes: CD spectra of OD1 (black), OD2 (orange), and OD3 (green) at pH 8.0, room 
temperature. Spectral data analysis was performed by Dr. Javier Seravalli in the UNL 
protein core facility. 
 
Figure 11: Guinea pigs immunization protocol. [Back to text] 
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Figure 12: Western blot analysis of antisera from immunized guinea pigs. [Back to text] 
 
Notes: Each band represents one independent Western blotting experiment. 4 serum 
samples from each group were used as the primary antibody against the assigned 
immunogens. All antigen-immunized groups showed antibody-binding activity to 
gp120, and here only one is shown as a positive control. All adjuvant-immunized 
group showed no antibody binding activity to OD1, OD2, OD3 and BSA (shows in 
Adjuvant 1, 2, 3, and 4 respectively). 
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Figure 13: ELISA analysis of antisera from immunized guinea pigs and their 
individual antigenic differences. [Back to text] 
 
Notes: 96-well plates were coated with three antigens, then were probed with 
dilutions of pre-bleed serum (day 0), test bleed serum (day 35, or final bleed serum 
(day 63). Experiments were performed in triplicate and figures represent an average 
data of multiple experiments. 
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Figure 14: ELISA analysis of antisera from immunized guinea pigs comparing 
antigenic differences among three immunogens. [Back to text] 
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Figure 15: Virus neutralization assay of antisera from immunized guinea pigs 
comparing serum neutralizing activities at different time points. [Back to text] 
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Notes: Neutralization assays of antisera from four groups of antigen-immunized or 
adjuvant-immunized groups. Neutralization activities were represented as the 
percentage (%) of reduction in relative luciferase units compared to wells with virus 
and cells only. Experiments were performed in triplicate and figures represent an 
average data of multiple experiments. 
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Figure 16: Virus neutralization assay of antisera from immunized guinea pigs 
comparing serum neutralizing activities of three immunogens. [Back to text] 
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Notes: Neutralization assays of antisera from four groups of antigen-immunized or 
adjuvant-immunized groups. Neutralization activities were represented as percentage 
(%) of reduction in relative luciferase units compared to wells with virus and cells 
only. Experiments were performed in triplicates and figures represent an average data 
of multiple experiments. 
 
Figure 17: Virus neutralization assay of antisera from OD3-immunized guinea pigs 
comparing serum neutralizing activities against diverse HIV-1-1 isolates and non-
HIV-1-1 isolate. [Back to text] 
 
Notes: Neutralization assays of antisera from four groups of antigen-immunized or 
adjuvant-immunized groups. Neutralization activities were represented as percentage 
(%) of reduction in relative luciferase units compared to wells with virus and cells 
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only. Experiments were performed in triplicates and figures represent an average data 
of multiple experiments. 
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